Hudock Inc. Has $1.37 Million Holdings in Pfizer Inc. (NYSE:PFE)

Hudock Inc. trimmed its position in Pfizer Inc. (NYSE:PFE) by 1.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,819 shares of the biopharmaceutical company’s stock after selling 564 shares during the quarter. Hudock Inc.’s holdings in Pfizer were worth $1,366,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Crumly & Associates Inc. boosted its holdings in Pfizer by 37.5% in the second quarter. Crumly & Associates Inc. now owns 10,995 shares of the biopharmaceutical company’s stock valued at $308,000 after acquiring an additional 2,998 shares during the last quarter. Beaumont Asset Management L.L.C. bought a new position in shares of Pfizer during the 2nd quarter worth approximately $471,000. First Dallas Securities Inc. boosted its stake in shares of Pfizer by 25.2% during the 2nd quarter. First Dallas Securities Inc. now owns 25,300 shares of the biopharmaceutical company’s stock worth $708,000 after acquiring an additional 5,100 shares during the period. Nicholas Hoffman & Company LLC. boosted its stake in Pfizer by 6.6% in the 2nd quarter. Nicholas Hoffman & Company LLC. now owns 44,230 shares of the biopharmaceutical company’s stock valued at $1,238,000 after purchasing an additional 2,730 shares during the period. Finally, Meridian Wealth Advisors LLC raised its holdings in Pfizer by 154.8% in the 2nd quarter. Meridian Wealth Advisors LLC now owns 39,436 shares of the biopharmaceutical company’s stock valued at $1,103,000 after acquiring an additional 23,958 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, August 19th. Finally, Barclays raised their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.01 on Thursday, reaching $28.40. 11,091,847 shares of the stock were exchanged, compared to its average volume of 38,283,742. The business has a 50 day moving average price of $29.03 and a two-hundred day moving average price of $28.04. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $160.93 billion, a price-to-earnings ratio of -477.09, a PEG ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $35.28.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were issued a $0.42 dividend. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.92%. Pfizer’s dividend payout ratio is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.